Progenics Pharma initiates clinical trial of 1095 radiotherapy
Category: #health  By Pankaj Singh  Date: 2019-06-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Progenics Pharma initiates clinical trial of 1095 radiotherapy

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, has recently announced that its first patient has been dosed for treatment of Metastatic Prostate cancer, in a phase 2 clinical study of 1095 radiotherapy. The clinical study evaluated I-131 1095 radiotherapy in combination with enzalutamide to treat mCRPC (metastatic castration resistant prostate cancer), reports source.

As per credible sources, a placebo controlled phase 2 clinical study is evaluating the efficiency of 1095 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer, who are new to chemotherapy, PSMA-avid & progressed on abiraterone. 18F-DCFPyL, the company’s patented imaging agent to visualize cancer, will be used to determine PSMA-avidity.

Nuclear Medicine Physician at LHSC, Scientist at Lawson Health Research Institute & Joseph’s Health Care London, Canada, Dr. David Laidley, was reported to say that 1095 radiotherapy is a potential treatment option for prostate cancer as it may overcome resistance developed to new androgen axis drugs, such as enzalutamide and abiraterone. Th resistance of anti-androgen drugs in the pre-chemotherapy patients is growing, which further reinforces need to advance new targeted therapies.

Asha Das, M.D., Chief Medical Officer, Progenics Pharmaceuticals, Inc., was reportedly quoted saying that phase 2 clinical study of 1095 radiotherapy to treat metastatic patients at an earlier stage utilizing a differentiated, PSMA-targeted approach, is a significant milestone.

Data from the study demonstrated 1095’s potential to reduce PSA & bone pain in heavily pretreated prostate cancer patients and was well tolerated. The preclinical data suggest combination of radiotherapy & enzalutamide is potentially a more effective treatment model for patients with mCRPC., Das added.

As per sources close to the matter, the study is expected to enroll 120 patients at 25 sites in Canada and the U.S. The study’s main endpoint is PSA (prostate specific antigen) response rate, according to PCWG3 (Cancer Clinical Trials Working Group 3). The criteria include a confirmed 50 per cent or greater decline from baseline. The secondary endpoint to evaluate response is based on RECIST (Response Evaluation Criteria in Solid Tumors), for soft tissue, PFS (progression free survival) and overall survival. Patients will be followed for 1 year after their first treatment of all efficacy endpoints.

Source credits: https://progenicsgc.gcs-web.com/news-releases/news-release-details/progenics-pharmaceuticals-doses-first-patient-phase-2-clinical

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...

Databricks buys 8080 Labs to boost its low code/no code offerings
Databricks buys 8080 Labs to boost its low code/no code offerings
By Pankaj Singh

California-based enterprise software company- Databricks has acquired German software startup 8080 Labs that developed bamboolib- a leading GUI for the Python-based Pandas data analysis and manipulation system. The purchase of 8080 Labs makes the fi...

Google rolls out GNI Advertising Lab for news publishers in India
Google rolls out GNI Advertising Lab for news publishers in India
By Pankaj Singh

American tech giant, Google LLC has recently announced the launch of Google News Initiative (GNI) Advertising Lab program for supporting small and medium-sized news publishers that generate original and accurate news for regional and local communitie...